IKT Stock Overview
A clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Inhibikase Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.43 |
| 52 Week High | US$4.20 |
| 52 Week Low | US$1.12 |
| Beta | 1.06 |
| 1 Month Change | -24.30% |
| 3 Month Change | -15.63% |
| 1 Year Change | -11.64% |
| 3 Year Change | -69.55% |
| 5 Year Change | n/a |
| Change since IPO | -95.91% |
Recent News & Updates
Recent updates
Can Inhibikase Therapeutics (NASDAQ:IKT) Afford To Invest In Growth?
Jan 25
Inhibikase stock rises 12% on FDA nod to start study of IkT-001Pro for leukemia
Aug 26Inhibikase Therapeutics GAAP EPS of -$0.18, revenue of $6.55M
Aug 12Will Inhibikase Therapeutics (NASDAQ:IKT) Spend Its Cash Wisely?
Aug 09Here's Why We're Watching Inhibikase Therapeutics' (NASDAQ:IKT) Cash Burn Situation
Apr 06Shareholder Returns
| IKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 26.6% | 1.3% | 0.2% |
| 1Y | -11.6% | 0.9% | 22.0% |
Return vs Industry: IKT underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: IKT underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| IKT volatility | |
|---|---|
| IKT Average Weekly Movement | 17.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IKT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IKT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 9 | Milton Werner | www.inhibikase.com |
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. Fundamentals Summary
| IKT fundamental statistics | |
|---|---|
| Market cap | US$156.56m |
| Earnings (TTM) | -US$19.57m |
| Revenue (TTM) | US$1.00 |
Over9,999x
P/S Ratio-8.3x
P/E RatioIs IKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IKT income statement (TTM) | |
|---|---|
| Revenue | US$1.00 |
| Cost of Revenue | US$13.02m |
| Gross Profit | -US$13.02m |
| Other Expenses | US$6.55m |
| Earnings | -US$19.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | -1,301,996,100.00% |
| Net Profit Margin | -1,956,524,900.00% |
| Debt/Equity Ratio | -13.5% |
How did IKT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 07:16 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inhibikase Therapeutics, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward White | H.C. Wainwright & Co. |
| Yuchen Ding | Jefferies LLC |
| Jason McCarthy | Maxim Group |